New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations
AstraZeneca s Tezspire has received a positive opinion from the. | January 13, 2023
Tezspire approved for self-administration in the EU in a new pre-filled pen New administration option for first and only severe asthma biologic approved in the EU with no phenotype or biomarker limitations AstraZeneca’s Tezspire (tezepelumab) has received a positive opinion from the Europea.
/CNW/ - Today, AstraZeneca and Amgen announced the Canadian availability of Tezspire™ (tezepelumab injection), indicated for the add-on maintenance treatment.
Tezspire approved in Japan for the treatment of severe asthma astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The .